The emerging role of checkpoint inhibitors in liver cancer

Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, comments on advances in the management of liver cancer. Current targeted therapies have failed to produce durable responses and have associated toxicities. Immune checkpoint inhibitors have demonstrated to be superior to tyrosine kinase inhibitors (TKIs) alone. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.